Eugene

[email protected]

LATEST

Merck & Co. Expands mRNA Cancer Vaccines Pact, Takes Equity Stake in Moderna
By

By
Merck & Co. and Moderna Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company focused on messenger RNA (mRNA) therapeutics, have expanded their 2016 collaboration to develop and commercialize mRNA cancer vaccines to…

AstraZeneca To Sell Rights to Antipsychotic Drug Seroquel for $538 Million
By

By
AstraZeneca has agreed to sell and license the rights in specified markets to its antipsychotic drugs, Seroquel (quetiapine fumarate) and Seroquel XR (quetiapine fumarate) for $538 million to Luye Pharma…

Teva Reports Double-Digit Revenue Declines But Says Restructuring On Track
By

By
Teva Pharmaceutical Industries has reported a revenue decline of 10%, in its first-quarter results, mainly related to the performance of its US generics business and lower sales of its top-selling…

FDA Issues CRL to Novartis’ Sandoz for Proposed Roche Biosimilar
By

By
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Sandoz, the generics arm of Novartis, regarding the company’s biologics license application (BLA) for its…

Janssen To Acquire Biopharm Company BeneVir in $1-Billion Deal
By

By
Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has agreed to acquire BeneVir Biopharm, a Rockville, Maryland-based biopharmaceutical company specializing in developing oncolytic immunotherapies, for up…

MHRA Issues Five-Year Plan for Post-Brexit
By

By
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a five-year corporate plan for 2018 to 2023 that highlights how the agency plans to address earlier outlined challenges…

Almac Appoints Head of Manufacturing Operations
By

By
Almac Group, a Craigavon, UK-based contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients (APIs) and drug products, has appointed David Taylor as Head of Manufacturing Operations. Taylor joined…

CordenPharma Expands Oligonucleotide Mfg
By

By
CordenPharma, a contract development and manufacturing organization of active pharmaceutical ingredients (APIs) and drug products, has expanded its commercial oligonucleotide API manufacturing at its CordenPharma Colorado site in Boulder, Colorado.…

Arena Pharmaceuticals in License Pact
By

By
Arena Pharmaceuticals, a San Diego-based biopharmaceutical company, and Outpost Medicine, a Lexington, Massachusetts-headquartered biopharmaceutical company focused on treatments for urologic and gynecologic diseases and disorders, have formed a licensing agreement…

Biogen Exercises Option for Investigational Alzheimer’s Disease Drug
By

By
Biogen has exercised its option in an agreement with Neurimmune, a Zurich, Switzerland-based biopharmaceutical company, to further reduce previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s…